当前位置:循环首页>正文

[CIT2010]生物可降解加多糖-蛋白质复合物涂层紫杉醇洗脱支架对比金属裸支架的多中心随机对照试验

作者:国际循环网   日期:2010/4/1 10:11:00

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

During the past years, we have also learned that some adverse effects, although rarely present, are more frequently associated with DES implantation, and might be linked to durable polymers......

    EUCATAX: A Multicenter Randomized Comparison of Paclitaxel-Eluting Stent with Biodegradable Polymer and Glycocalix Coating vs. Bare Metal Stent
Alfredo E. Rodriguez

    During the past years, we have also learned that some adverse effects, although rarely present, are more frequently associated with DES implantation, and might be linked to durable polymers, which were always present in the first DES designs. Biodegradable polymers have the advantage of inducing a reduced inflammatory response, allowing the immunosuppressive agent to be completely released and eluted after degradation of the polymer.
The purpose of the present phase IV randomized clinical trial was to compare the efficacy and safety of a new DES design with a dual coating lawyer, a biodegradable polymer and glycocalyx, versus a bare metal stent (BMS) design in a wide patient/lesion subset.

    The first in man observational study with this technology has been previously conducted. From August 1st 2007 to August 31st 2009, from 2383 patients treated in the catheterization laboratories of the participant hospitals that were eligible for the study and met the inclusion criteria, 422 were randomized in the EUCATAX trial. 211 were included in PES with biodegradable polymer and glycocalyx coating and 211 in BMS arm. Cumulative clinical events at 17.3 ± 7.3 months was obtained in both groups. As we can see in Table, incidence of TVR was 8.2% in the PES versus 14.9% in the BMS group (P=0.02); TLR was 6.1% in the PES versus 12.5% in the BMS group (P=0.01). Incidence of TVF (9.5% vs 17.1% in the PES and BMS arms, respectively, P=0.02) and MACCE (10% vs 19% in the PES and BMS arms, respectively, P=0.009), which correspond to the major end points of the study, were also significantly improved in the eluted stent group .

    Table.  Clinical Outcome of eucaTAX Trial:Cumulative results at 17.3 months of follow up

 

     At nine months, the rates of TVF (per protocol first end point) were 6.6% versus 14.7%
in the PES and BMS arms, respectively (P=0.024), and the rate of MACCE was 7.1% in the PES and 16.1% in the BMS group (P=0.016).  Incidence of any ST was 1.4% in the PES and 1.9% in the BMS group;beyond one year, ST was non found in any group.

    In the  Figure  we can observed survival freedom from TVF which indicate a significant improvement in the PES arm. Freedom from TVF was 90.5% in the PES versus 82.9% in the BMS arm, meaning a 44.5% reduction of this event (P=0.02).

    Figure. Survival curve from TVF:17.3 months of follow up from eucaTAX Trial

    Finally presence of incomplete stent malapposition was more frequently seen in
the BMS arm: 9/37 (24.3%) versus 5/45 (11.1%) in the PES arm, respectively, (P=0.15). These differences were significantly in favor to the PES in proximal stent border (P=0.015). This unique IVUS finding was no reported previously with any DES technology.

    In conclusion, at 17.3 months of follow up, patients treated with this novel DES technology had significant lower incidence of TVF and MACCE than those treated with a BMS design.
 

版面编辑:沈会会



Glycocalix金属裸支架

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530